Supercharge Your Innovation With Domain-Expert AI Agents!

Extended release conjugates of exenatide analogs

A conjugate, sustained-release technology, applied in the direction of hormone peptides, specific peptides, drug combinations, etc., can solve problems such as instability of the original mixture

Inactive Publication Date: 2019-03-01
PROLYNX LLC
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these products form an interchange system and are unstable to the original mixture equilibrated to the products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extended release conjugates of exenatide analogs
  • Extended release conjugates of exenatide analogs
  • Extended release conjugates of exenatide analogs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] Preparation of Azido-Linker-[N28Q]Exenatide of Formula (4)

[0240] Among them, R 1 = CN or MeSO 2 ; 2 = H; an R 5 = H and other R 5 =(CH 2 ) 5 N 3 ;P=N α -[N28Q] Exenatide

[0241] use Rink amide resin (0.5 meq / g) in Peptides were synthesized by standard solid-phase methods on a peptide synthesizer. Fmoc-amino acid (5 equiv / coupling) to the N-terminus of the peptide chain using HCTU (4.9 equiv / coupling) and N,N-diisopropylethylamine (10 equiv / coupling) in DMF at ambient temperature Double-couple. The Fmoc group was removed using 20% ​​4-methylpiperidine in DMF. [N28Q]Exenatide was deprotected and cleaved from the resin using 95:2.5:2.5 trifluoroacetic acid / triisopropylsilane / dithiothreitol.

[0242] Use the PeakScientific Shimadzu for 5μC18 column (50x 20mm ID) TM Crude [N28Q]exenatide (22 mg) was purified on a semi-preparative scale by the LC-20AD system using a linear gradient of 30%-60% MeCN (0.1% TFA) in water (0.1% TFA) elution. The purest ...

Embodiment 2

[0248] Preparation of PEG Hydrogel Microspheres

[0249] Using 2 reagents (2-reagent) Hydrophobic flow focusing microfluidic chip (Dolomite) with 7 parallel 50um droplet forming channels. Fluids are controlled by a pneumatically driven pump that functions similarly to the Miltos pressure pump made by Dolomite Microfluidics Dolomite. These pumps use compressed air to drive liquids through microfluidic chips. The drive pressure was computer controlled using an appropriate pressure regulator (MPV series from ProportionAir) to maintain a steady flow rate by using a feedback loop from a liquid flow sensor (SLI-0430 from Sensirion). This type of fluid control is scalable to deliver fluids from multi-liter reservoirs, and handles flow rates with about 1% standard error, which is better than syringe pumps that typically have as much as 20% oscillation in their flow rates. The system was used to deliver both hydrogel prepolymer solutions as well as the continuous phase. Typical fl...

Embodiment 3

[0254] Preparation of cyclooctyne-microspheres

[0255] The reaction was carried out in a syringe reaction vessel as shown below. To each 4 mL amino-microsphere packing suspension in MeCN containing 2 μmol amine / mL was added 32 μmol DIPEA (4 equiv) in 1 mL MeCN, and 9.6 μmol (1.2 equiv) of 1-fluoro-2- Pentafluorophenyl cyclooctyne-1-carboxylate (MFCO-PFP). After 1 hour of shaking at ambient temperature, a small amount (~50 uL) of microspheres was expelled from the outlet of the syringe and treated with 0.5 mL of 0.04% w / v TNBS in 0.1 M sodium borate (pH ~9.3) (1) for 30 min; The initial amino-microspheres (with a dark orange color) compared to the microsphere color matched the TNBS solution to indicate a complete reaction. After the reaction, by adding 8 μmol (1 eq.) of Ac in 1 mL of MeCN 2 O for 10 minutes to cap the microspheres. After removing the supernatant, approximately 2 mL of microspheres were transferred to a second 10 mL syringe, each slurry was washed with 4 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Extended-release conjugates of stabilized GLP-1 agonists balance agonist stability with release rates to provide long lasting administration to treat diabetes and related conditions on once-a-month orless frequent dosing schedules.

Description

technical field [0001] The present invention relates to the field of drug delivery and sustained release formulations. More specifically, it relates to sustained release compositions that deliver a stable form of a GLP-1 agonist over a period of one month or more. Background technique [0002] Exenatide is a potent agonist of the GLP-1 receptor with a 39 amino acid peptide, which makes it a glucose-regulating insulin secretagogue. It is widely used as a free peptide in the treatment of type II diabetes to (Astra-Zeneca), the peptide is injected twice daily due to its short in vivo half-life of 2.5 hours. It would be highly desirable to extend the half-life of exenatide and related GLP-1 agonist peptides, thereby improving their efficacy, reducing side effects and reducing the burden of treatment for patients. [0003] Peptide half-life has traditionally been extended by one or a combination of several methods: (i) chemical modification of the peptide to delay metabolism;...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00C07K14/605
CPCC07K14/605A61K47/60A61K47/6903A61P3/10A61K38/00A61P3/00A61K38/26A61K47/65A61K9/0004
Inventor E·L·施奈德B·赫恩J·C·海尼斯G·W·阿什利D·V·桑蒂
Owner PROLYNX LLC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More